1613307-27-9

Upstream product

• 473923-97-6 3-chloro-5-hydroxybenzonitrile 
• 105-36-2 ethyl bromoacetate 
• 6575-00-4 3,5-dichlorobenzonitrile 
• 100-42-5 styrene 

Downstream Products

• 1338225-97-0 3-chloro-5-((1-((4-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl)-2-oxo-4-(trifluoromethyl)-1,2-dihydropyridin-3-yl)oxy)benzonitrile 
• 1155846-86-8 3-chloro-5-((2-oxo-4-(trifluoromethyl)-1,2-dihydropyridin-3-yl)oxy)benzonitrile 
• 1613307-28-0 (2E/Z,4E)-ethyl 2-(3-chloro-5-cyanophenoxy)-5-ethoxy-3-(trifluoromethyl)penta-2,4-dienoate 

Relevant academic research and scientific papers

PROCESS FOR MAKING REVERSE TRANSCRIPTASE INHIBITORS

The present invention is directed to a novel process for synthesizing 3-(substituted phenoxy)-1-[(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl])-pyridin-2(1H)-one derivatives. The compounds synthesized by the processes of the invention are HIV reverse transcriptase inhibitors useful for inhibiting reverse transcriptase and HIV replication, and the treatment of human immunodeficiency virus infection in humans.

Highly efficient synthesis of hiv nnrti doravirine

The development of an efficient and robust process for the production of HIV NNRTI doravirine is described. The synthesis features a continuous aldol reaction as part of a de novo synthesis of the key pyridone fragment. Conditions for the continuous flow aldol reaction were derived using microbatch snapshots of the flow process.

PROCESS FOR MAKING REVERSE TRANSCRIPTASE INHIBITORS

The present invention is directed to a novel process for synthesizing 3-(substituted phenoxy)-1-[(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl])-pyridin-2(1H)-one derivatives. The compounds synthesized by the processes of the invention are HIV reverse t